Viewing data from:

PAZOPANIB HYDROCHLORIDE

ANDA

PAZOPANIB HYDROCHLORIDE | A217517 | TEVA PHARMACEUTICALS INC

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: VOTRIENT(TE code: AB)

API Supply Chain11 active DMFs1 inactive

11 active API suppliers hold Drug Master Files for this ingredient.

HETERO LABS LTDPAZOPANIB HYDROCHLORIDE

DMF 262072012

MSN LABORATORIES PRIVATE LTDPAZOPANIB HYDROCHLORIDE [ROUTE CODE - "PY"]

DMF 274222013

FORMOSA LABORATORIES INCPAZOPANIB HYDROCHLORIDE

DMF 312972017

CIPLA LTDPAZOPANIB HYDROCHLORIDE

DMF 328992018

ZHEJIANG LEPU PHARMACEUTICAL CO LTDPAZOPANIB HYDROCHLORIDE

DMF 341462019

DR REDDYS LABORATORIES LTDPAZOPANIB HYDROCHLORIDE

DMF 357322021

GRANULES INDIA LTDPAZOPANIB HYDROCHLORIDE

DMF 360372021

MEDICHEM SAPAZOPANIB HYDROCHLORIDE

DMF 361922021

SUN PHARMACEUTICAL INDUSTRIES LTDPAZOPANIB HYDROCHLORIDE

DMF 365502022

LAURUS LABS LTDPAZOPANIB HYDROCHLORIDE

DMF 366892022

SYNTHIMED LABS PRIVATE LTDPAZOPANIB HYDROCHLORIDE

DMF 414812025

INTAS PHARMACEUTICALS LTDInactivePAZOPANIB HYDROCHLORIDE

DMF 346932020

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Nov 30, 2023	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — EQ 200MG BASE

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Oct 19, 2023

No patent or exclusivity listings for this strength.